Patents by Inventor Jack F. Youngren

Jack F. Youngren has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TYROSINE KINASE RECEPTOR ANTAGONISTS AND METHODS OF TREATMENT FOR PANCREATIC CANCER
    Publication number: 20120214758
    Abstract: A method of treatment is disclosed whereby cancer cells are brought into contact with a formulation comprising an inhibitor of tyrosine kinase receptors. The formulation may be comprised of an injectable carrier and two or more tyrosine kinase receptor inhibitors which may be nordihydrogluaiaretic acid (NDGA) and doxyrubicine.
    Type: Application
    Filed: February 17, 2012
    Publication date: August 23, 2012
    Applicant: The Regents of the University of California
    Inventors: Ira GOLDFINE, John Kerner, Betty A. Maddux, Michael Campbell, Jack F. Youngren, Peter Kushner
  • Tyrosine kinase receptor antagonists and methods of treatment for breast cancer
    Patent number: 8143226
    Abstract: A method of treatment is disclosed whereby cancer cells are brought into contact with a formulation comprising an inhibitor of tyrosine kinase receptors. The formulation may be comprised of an injectable carrier and two or more tyrosine kinase receptor inhibitors which may be nordihydroguaiarectic acid (NDGA) and doxorubicin.
    Type: Grant
    Filed: October 25, 2006
    Date of Patent: March 27, 2012
    Assignee: The Regents of the University of California
    Inventors: Ira Goldfine, John Kerner, Betty A. Maddux, Michael Campbell, Jack F. Youngren, Peter Kushner
  • INHIBITORY EFFECTS OF NORDIHYDROGUAIARETIC ACID (NDGA) ON THE IGF-1 RECEPTOR AND ANDROGEN DEPENDENT GROWTH OF LAPC-4 PROSTATE CANCER CELLS
    Publication number: 20090280112
    Abstract: Disclosed herein are methods and compositions for the treatment of prostate cancer with an IGF-1 receptor kinase inhibitor. Methods are also provided for the treatment of prostate cancer by identifying a level of IGF-1 receptor expression and making a decision whether to treat with an IGF-1 receptor kinase inhibitor.
    Type: Application
    Filed: May 1, 2009
    Publication date: November 12, 2009
    Inventors: IRA D. Goldfine, Jack F. Youngren, Michael J. Campbell, Betty A. Maddux, John A. Kerner, Charles J. Ryan